BioPharma Resources

Drug Trial Radar · NCT06549595

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,018 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,018

Planned (sponsor's estimate)

Start

Aug 7, 2024

Primary completion

Nov 26, 2031

Study completion Nov 26, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Conditions

  • Untreated Follicular Lymphoma

Interventions

  • SurovatamigDrug

    a fully human bispecific monoclonal IgG4 antibody

  • R-CHOPDrug

    Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone

  • R-CVPDrug

    Rituximab, Cyclophosphamide, Vincristine and Prednisone

  • BRDrug

    Bendamustine, Rituximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEsTime frame: Up to 10 years
  2. SRI Primary: Determination of the recommended Phase III dose (RP3D)Time frame: Up to 1 year
  3. Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapyTime frame: Up to 10 years
  4. Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapyTime frame: Up to 10 years

Locations

244 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama · Recruiting

  • Research Site

    Anchorage, Alaska · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Clovis, California · Not yet recruiting

  • Research Site

    Los Alamitos, California · Recruiting

  • Research Site

    San Diego, California · Not yet recruiting

  • Research Site

    Santa Monica, California · Not yet recruiting

  • Research Site

    Aurora, Colorado · Withdrawn

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Newark, Delaware · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Macon, Georgia · Recruiting

  • Research Site

    Evanston, Illinois · Not yet recruiting

  • Research Site

    Peoria, Illinois · Not yet recruiting

  • Research Site

    Fort Wayne, Indiana · Recruiting

  • Research Site

    Des Moines, Iowa · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Not yet recruiting

  • Research Site

    Baton Rouge, Louisiana · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Bethesda, Maryland · Recruiting

  • Research Site

    Columbia, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Ypsilanti, Michigan · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Saint Paul, Minnesota · Not yet recruiting

  • Research Site

    Chesterfield, Missouri · Not yet recruiting

  • Research Site

    Springfield, Missouri · Recruiting

  • Research Site

    Hackensack, New Jersey · Not yet recruiting

  • Research Site

    New Brunswick, New Jersey · Not yet recruiting

  • Research Site

    Albany, New York · Recruiting

  • Research Site

    Brooklyn, New York · Not yet recruiting

  • Research Site

    Mineola, New York · Not yet recruiting

  • Research Site

    New Hyde Park, New York · Not yet recruiting

  • Research Site

    New York, New York · Recruiting

Showing 40 of 244 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.